In contrast to the very high transplant-related mortality (TRM) associated with the early experience of cord blood (CB) transplantation (CBT), recent transplant series have been associated with comparable survival to that of human leucocyte antigen (HLA)-matched unrelated donor transplantation in children with similarly promising results in adults. Consequently, the use of CB as an alternative stem cell source and the global inventory of units in public banks are rapidly increasing although challenges remain. This review will address efforts to optimize CBT from 3 different perspectives: that of the transplant center, the CBT registry, and the CB bank
AbstractWorldwide >10 million adults and 250 000 cord blood units are available for unrelated HCT. H...
Optimizing cord blood donor selection based mainly on cell dose and human leukocyte antigen (HLA) di...
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for a variety...
In contrast to the very high transplant-related mortality (TRM) associated with the early experience...
Allogeneic transplant access can be severely limited for patients of racial and ethnic minorities wi...
Use of unrelated donor cord blood (CB) as an alternative stem cell source is increasing, and yet the...
Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell tra...
AbstractUnrelated-donor umbilical cord blood (CB) is a useful alternative hematopoietic stem cell so...
The donor selection algorithm for cord blood (CB) with regards to matched related and unrelated dono...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
Cord blood (CB) transplantation has expanded the ability of the transplantation community to meet th...
AbstractThe Cord Blood Transplantation study group conducted a prospective study of unrelated cord b...
Background: Cord-blood banks have increased the use of cord-blood transplantation in patients with h...
AbstractUmbilical cord blood hematopoietic stem cells coming from related or unrelated donors are an...
Hematopoietic stem cell transplantation has been established as a lifesaving therapy for leukemias o...
AbstractWorldwide >10 million adults and 250 000 cord blood units are available for unrelated HCT. H...
Optimizing cord blood donor selection based mainly on cell dose and human leukocyte antigen (HLA) di...
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for a variety...
In contrast to the very high transplant-related mortality (TRM) associated with the early experience...
Allogeneic transplant access can be severely limited for patients of racial and ethnic minorities wi...
Use of unrelated donor cord blood (CB) as an alternative stem cell source is increasing, and yet the...
Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell tra...
AbstractUnrelated-donor umbilical cord blood (CB) is a useful alternative hematopoietic stem cell so...
The donor selection algorithm for cord blood (CB) with regards to matched related and unrelated dono...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
Cord blood (CB) transplantation has expanded the ability of the transplantation community to meet th...
AbstractThe Cord Blood Transplantation study group conducted a prospective study of unrelated cord b...
Background: Cord-blood banks have increased the use of cord-blood transplantation in patients with h...
AbstractUmbilical cord blood hematopoietic stem cells coming from related or unrelated donors are an...
Hematopoietic stem cell transplantation has been established as a lifesaving therapy for leukemias o...
AbstractWorldwide >10 million adults and 250 000 cord blood units are available for unrelated HCT. H...
Optimizing cord blood donor selection based mainly on cell dose and human leukocyte antigen (HLA) di...
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for a variety...